COVID-19chronic viral inflammatory syndromecytokinesimmune-mediated inflammatory diseaseNLRP3 activationsenescent activated secretory phenotypeSince the emergence of SARS-COV-2, many updates and assumptions are being discussed based on the emerging understanding of the pathophysiology and outcomes of the ...
Bacterial co-infection is a known major source of sickness and death in the context of other respiratory viral infections such as influenza, parainfluenza or RSV. However, it has been unclear regarding the frequency of bacteremic co-infection in COVID-19 and the impact it has on clinical outco...
inflammatory responses and regulating immune function. Immune system dysfunction is considered to increase the risk of viral infections, such as SARS-CoV-2, and was observed in different pathological situations. Obese patients develop severe COVID-19 sequelae, due to the high concentrations of TNF-α...
With a viral disease like COVID, a drug considered for repurposing should show one of these three qualities: it should either be able to inhibit one or more stages of the coronavirus's replication cycle; relieve the bad effects of the virus; or manipulate the immune system so that the body...
Background The SARS-CoV-2 virus continues to spread rapidly across the globe afflicting many with Coronavirus Disease 2019 (COVID-19). As the infection rates rise, a growing number of SARS-CoV-2 positive individuals have been reported to complain of olfactory disturbances at an alarming rate....
patients must have had positive SARS-CoV-2 viral test and, they must also be unable to use alternative COVID-19 treatment options, due to being inaccessible or being clinically inappropriate. How does molnupiravir work? Molnupiravir is an oral antiviral medicine that works by decreasing the ...
People infected with COVID-19 can still be contagious even when they stop feeling sick, so precautionary measures should continue for at least 2 weeks after symptoms disappear and until the COVID-19 test result is negative. Ideally, patients should be qu
Most of the ongoing projects aimed at the development of specific therapies and vaccines against COVID-19 use the SARS-CoV-2 spike (S) protein as the main target. The binding of the spike protein with the ACE2 receptor (ACE2) of the host cell constitutes the first and key step for vir...
inflammation caused by bacterial orviral infectionsor medications, again mostly in teen boys and young men. Oster said one theory is that testosterone and puberty play a role, which is partly why many experts expect any vaccine-related risk would be lower for younger kids getting a smaller dose...
The SARS-CoV-2 virus does not infect blood vessels, despite the high risk of blood clots to COVID-19 patients, University of Queensland researchers have found. Dr. Emma Gordon and Dr. Larisa Labzin from UQ's Institute for Molecular Bioscience and Dr. Kirsty Short from UQ's School of Che...